Key Statistics
$180B+
Brand revenue at risk 2025–2028
US market only
85+
Blockbusters losing exclusivity
Primary patent expiry 2025–2028
340+
Para IV filings tracked
Active FTF challenges as of Q1 2026
180d
FTF exclusivity window value
Avg. FTF profit: $40–200M per drug
12
High-value targets (>$1B brand rev)
FTF opportunity > $80M estimated
2026
Peak cliff year
Largest single-year exclusivity loss wave
Target Profile
| Scope | 85+ small-molecule brand drugs losing primary US patent exclusivity between 2025 and 2028 — with active or anticipated Para IV challenges mapped |
|---|---|
| Top Therapeutic Classes | Immunology / Biologics (small-mol analog)Oncology oralDiabetes / MetabolicCardiovascularCNS / NeurologyRespiratory |
| FTF Complexity Drivers | Patent thickets (10–30 patents)Pediatric exclusivity extensionsCitizen petitions (delay tactics)NCE 5-year exclusivitySettlement / reverse payment risk |
| Top FTF Filers | Teva · Mylan (Viatris) · Sun Pharma · Apotex · Hikma · Aurobindo · Amneal · Sandoz (Hexal) · Dr. Reddy's · Lupin |
| Regulatory Path | ANDA (Para IV) filing → 30-month stay → litigation → settlement or district court ruling → 180-day exclusivity clock starts |
340Para IV filed
180In litigation
95Settlement reached
18FTF exclusivity active
12At-risk launch
42Market entry complete
Drug Landscape
| Drug Name | Company | Modality | Indication | Stage | Mechanism |
| Eliquis (apixaban) | BMS / Pfizer vs. Teva et al. | Small molecule | Anticoagulation | Patent cliff 2026 | ~$12B US revenue at risk · FTF exclusivity highly contested |
| Xarelto (rivaroxaban) | Bayer / J&J vs. Mylan et al. | Small molecule | Anticoagulation | Patent cliff 2027 | ~$4.5B US revenue · Multiple Para IV challengers |
| Ibrance (palbociclib) | Pfizer vs. Sun et al. | Small molecule | Breast Cancer | Patent cliff 2027 | ~$3.8B US revenue · Composition patent expires 2027 |
| 🔒 Top FTF Asset A | Multiple challengers | — | Locked | 2026 cliff | Details in paid report |
| 🔒 85+ more drugs... | Multiple brands | — | Various | 2025–2028 | Full landscape in paid report |
#GenericDrugs#PatentCliff#FirstToFile#ParaIV#ANDA#PharmaceuticalPatents#GenericsIndustry#DrugPricing#MarketAccess#PharmaceuticalIndustry#IntellectualProperty